

| NAME Dr. Ioanna Maroulakou | | POSITION TITLE Professor of Genetics | |
|--------------------------------------|---------------------------|---|--------------------|
| EDUCATION/TRAINING | | | |
| INSTITUTION AND LOCATION | DEGREE (if applicable) | YEAR(s) | FIELD OF STUDY |
| University of Athens, Athens Greece | B.S. | 1984 | Biology |
| University of Athens, Athens Greece | Ph.D. | 1990 | Biology |
| National Cancer Institute, NIH, USA | Postdoc | 1991-1996 | Molecular Oncology |

Positions and Honors

- 1984-1990 Graduate Student, Laboratory of Biology, School of Health Sciences, University of Athens, Athens, Greece
- 1988 Guest Investigator Fellowship, Laboratory of Cell Biology, Rockefeller University, New York, USA
- 1991-1996 Post-doctoral Fellow, Laboratory of Molecular Oncology, National Cancer Institute, USA
- 1996-2003 Assistant Professor, Dept. of Medicine, Medical University of South Carolina, Charleston, USA
- 2003-2009 Assistant Professor, Dept. of Medicine, Tuft University School of Medicine, Boston, USA
- 2003-2009 Investigator, Molecular Oncology Research Institute, Tufts-NEMC, Boston, USA
- 2009 Associate Professor, Dept. of Pharmacology and Toxicology, Cancer Institute, University of Mississippi Medical Center, Jackson, USA
- 2010 - today Professor of Genetics, Dept. of Molecular Biology and Genetics, Democritus University of Thrace, Greece

Professional Memberships

- Member, American Association for Cancer Research
- Member, American Association for the Advancement of Science
- Member, *European Association for Cancer Research*
- Member, Hellenic Society of Biochemistry and Molecular Biology
- Member, Hellenic Association of Medical Geneticists

Other Experience and Professional Activities

- 2010- today Head of Cancer Genetics and Acquired Genetic diseases Laboratory
- 2013- today Director of the MscProgramme "Translational Research in Biomedicine"

Honors and Awards

- 9/86-9/90 National Graduate Fellowship, University of Athens, Greece
- 9/87 Grant from European Training Programme (ETP) in Italy
- 6/88-12/88 Guest Investigator Fellowship, Laboratory of Cell Biology, Rockefeller University, USA
- 6/91-6/93 Fogarty Fellowship, Laboratory of Molecular Oncology, National Cancer Institute, NIH, USA
- 6/93-5/96 Renewal of Fogarty Fellowship, Laboratory of Molecular Oncology, National Cancer Institute, NIH, USA

Selected Peer-reviewed Publications

Georgatos SD, **Maroulakou I**, Blobel G. Lamin A, lamin B, and lamin B receptor analogues in yeast. J Cell Biol. 1989 Jun;108(6):2069-82.

Maroulakou IG, Stylianopoulou F. The effects of adrenalectomy and thermal stress on glutamic acid decarboxylase activity in different regions of the rat brain. Neurochem Res. 1991 Dec;16(12):1265-8.

Maroulakou IG, Kitraki E, Stylianopoulou F. Stress affects the activated form of the corticosteroid-receptor complex in the rat brain. J Neuroendocrinol. 1992 Feb;4(1):15-9

Maroulakou, I. G., Papas, T. S., and Green, J. E.: Differential expression of ets-1 and ets-2 proto oncogenes during murine embryogenesis. Oncogene 9: 1551-1565, 1994.

Maroulakou, I. G., Anver, M., Garrett, L., and Green, J. E.: Prostate and breast cancer in transgenic mice carrying a rat C3(1) SV40 TAG fusion gene. Proc. Natl. Acad. Sci. USA 91: 11236-11240, 1994.

Maroulakou, I. G, Pokholok, D. K., Cuprash, D. V., Alimzhanov, M. B., Kozlov, S. V., Novobrantseva, T. I., Turetskaya, R. L., Green, J. E., and Nedospasov, S. A.: Cloning and in situ transcriptional analysis of the murine lymphotoxin-b (Ltb) gene. Proc. Natl. Acad. Sci. USA 92: 674-678, 1995. (Note: In this paper Maroulakou and Pokholok are equal first authors)

Byeon MK, Westerman MA, **Maroulakou IG**, Henderson KW, Suster S, Zhang XK, Papas TS, Vesely J, Willingham MC, Green JE, Schweinfest CW. The down-regulated in adenoma (DRA) gene encodes an intestine-specific membrane glycoprotein. Oncogene. 1996 Jan 18;12(2):387-96.

Chen S-L, **Maroulakou IG**, Green JE, Romano-Spica V, Modi W, Lautenberger J, Bhat NK. Isolation and characterization of a novel gene expressed in multiple cancers. Oncogene. 1996;12:741-751

Kenney, N. J., Smith, G. H., **Maroulakou, I.**, Johnson, G., Gullick, W. J., Green, J. E., Muller, W. J., Merlino, G. H., Callahan, R., Salomon, D. S., and Dickson, R. B.: Detection of amphiregulin and Cripto-1 in mammary tumors from transgenic mice. Molecular Carcinogenesis 15: 44-56, 1996.

Shibata, M.-A., **Maroulakou, I. G.**, Jorcyk, C. L., Gold, L. G., Ward, J. M., and Green, J. E.: p-53 independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: Suppression of apoptosis during the transition from preneoplasia to carcinoma. Cancer Research 56(13): 2998-3003, 1996.

Jorcyk, C. L., Garrett, L. J., **Maroulakou, I. G.**, Watson, D. K., and Green J. E.: Multiple regulatory regions control the expression of the Ets-1 proto-oncogene in the developing mouse. Cellular and Molecular Biology 43: 211-225, 1997.

Maroulakou, I., Shibata, M.-A., Jorcyk, C. L., Chen, X. X. and Green, J. E.: Reduced p53 dosage associated with mammary tumor metastases in C3(1)TAG transgenic mice. Molecular Carcinogenesis 20: 168-174, 1997.

Yoshidome, K., Shibata, M. A., **Maroulakou, I. G.**, Liu, M. L., Jorcyk, C. L., Gold, L. G., Welch, V. N. and Green, J. E.: Genetic alterations in the development of mammary and prostate cancer in the C3(1)/Tag transgenic mouse model. Int. J. Oncol. 12(2): 449-453, 1998.

Jorcyk CL, Liu ML, Shibata MA, **Maroulakou IG**, Komschlies KL, McPhaul MJ, Resau JH, Green JE. Development and characterization of a mouse prostate adenocarcinoma cell line: ductal formation determined by extracellular matrix. Prostate. 1998 Jan 1;34(1):10-22.

Maroulakou, I. G., Shibata, M.-A., Anver, M. R., Roberts, A., Tsarfaty, I., Resau, J., Ward, J. M. and Green, J. E.: Heterotopic endochondral ossification associated with mixed tumor formation in C3(1)/Tag transgenic mice is associated with elevated TGF-beta1 and BMP-2 expression. Oncogene 18(39): 5435-5447, 1999.

Maroulakou IG, Bowe DB. Expression and function of Ets transcription factors in mammalian development: a regulatory network. Oncogene. 2000 Dec 18;19(55):6432-42.

Bowe, D. B., Kenney, N. J., Adereth Y. and **Maroulakou, I. G.**: Suppression of her2/neu mammary tumor growth in Cyclin D1-deficient mice is compensated for by cyclin E. Oncogene, 21:291-298, 2002 (corresponding author).

Highlighted in The New England Journal of Medicine, section Clinical Implications of Basic Research, entitled "The Reciprocal Dance between Cancer and Development" by Lewis A. Chodosh. 2002. Vol. 347 (2):134-136.

Tomczak MF, Gadjeva M, Wang YY, Brown K, **Maroulakou I**, Tschlis PN, Erdman SE, Fox JG, Horwitz BH. Defective activation of ERK in macrophages lacking the p50/p105 subunit of NF-kappaB is responsible for elevated expression of IL-12 p40 observed after challenge with Helicobacter hepaticus. J Immunol. 2006 Jan 15;176(2):1244-51.

Maroulakou IG, Oemler W, Naber SP, Tschlis PN. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in Mouse Mammary Tumor Virus (MMTV)-ErbB2/Neu and Polyoma Middle T mice. Cancer Res 2007; 67(1): 167-77. (Corresponding Author).

Highlighted in the front page of "Cancer Research" as selected article from the January 1, 2007 issue.

Mao C, Tili EG, Dose M, Haks MC, Bear SE, **Maroulakou I**, Horie K, Gaitantris G, Ludwig T, Wiest DL, Gounari F, Tschlis PN. Unequal contribution of akt isoforms in the double-negative to double-positive thymocyte transition. J. Immunol. 2007 May 1;178(9):5443-53.

Maroulakou IG, Oemler W, Naber SP, Tschlis PN. Distinct roles of the three Akt isoforms in lactogenic differentiation and involution. J Cell Physiol. 2008 Nov;217(2):468-77. (Corresponding Author)

Wright, G., **Maroulakou, I.**, Vijayalakshmi, S., Eldridge, J., Tschlis, P., and Muise-Helmericks, R.C. VEGF Stimulation of Mitochondrial Biogenesis: Requirement of Akt3 kinase. FASEB J. 2008 Sep 22(9):3264-75

Iliopoulos D, Polytharchou C, Hatziapostolou M, Kottakis F, **Maroulakou IG**, Struhl K, Tschlis PN. MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Science Signal. 2009 Oct 13;2(92):ra62.

Polytharchou C., Iliopoulos D., Hatziapostolou M., Kottakis F, **Maroulakou, I.**, Kevin Struhl K., and Tschlis P. Akt2 functions as a master regulator of all Akt isoforms and promotes resistance to hypoxia by regulating the induction of miR-21 upon oxygen deprivation. Cancer Research. 2011 Jul 1;71(13):4720-31.

Hebron E, Hope C, Kim J, Jensen JL, Flanagan C, Bhatia N, **Maroulakou I**, Mitsiades C, Miyamoto S, Callander N, Hematti P, Asimakopoulos F. MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes/macrophages. Br J Haematol. 2013 Mar;160(6):779-84.

Hope C, Ollar SJ, Heninger E, Hebron E, Jensen JL, Kim J, **Maroulakou I**, Miyamoto S, Leith C, Yang DT, Callander N, Hematti P, Chesi M, Bergsagel PL, Asimakopoulos F. TPL2 kinase regulates the inflammatory milieu of the myeloma niche. Blood. 2014 May 22;123(21):3305-15.

Jensen JL, Rakhmilevich A, Heninger E, Broman AT, Hope C, Phan F, Miyamoto S, **Maroulakou I**, Callander N, Hematti P, Chesi M, Bergsagel PL, Sondel P, Asimakopoulos F. Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma. Cancer Immunol Res. 2015 Aug;3(8):881-90.

Arelaki S, Arampatzioglou A, Kambas K, Papagoras C, Miltiades P, Angelidou I, Mitsios A, Kotsianidis I, Skendros P, Sivridis E, **Maroulakou I**, Giatromanolaki A, Ritis K. Gradient Infiltration of Neutrophil Extracellular Traps in Colon Cancer and Evidence for Their Involvement in Tumour Growth. PLoS One. 2016 May 2;11(5):e0154484.

Hope C, Foulcer S, Jagodinsky J, Chen SX, Jensen JL, Patel S, Leith C, **Maroulakou I**, Callander N, Miyamoto S, Hematti P, Apte SS, Asimakopoulos F. Immunoregulatory roles of versican proteolysis in the myeloma microenvironment. Blood. 2016 Aug 4;128(5):680-5.

Dovrolis N, Kolios G, Spyrou G, **Maroulakou I**. Laying in silico pipelines for drug repositioning: a paradigm in ensemble analysis for neurodegenerative diseases. Drug Discov Today. 2017 May;22(5):805-813.